EP Wealth Advisors LLC Acquires 3,790 Shares of Emergent Biosolutions Inc. $EBS

EP Wealth Advisors LLC raised its holdings in Emergent Biosolutions Inc. (NYSE:EBS) by 33.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,249 shares of the biopharmaceutical company’s stock after purchasing an additional 3,790 shares during the quarter. EP Wealth Advisors LLC’s holdings in Emergent Biosolutions were worth $74,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of EBS. Northern Trust Corp grew its stake in Emergent Biosolutions by 2.6% in the 4th quarter. Northern Trust Corp now owns 145,889 shares of the biopharmaceutical company’s stock valued at $1,395,000 after purchasing an additional 3,692 shares during the period. Bank of America Corp DE grew its stake in Emergent Biosolutions by 4.4% in the 4th quarter. Bank of America Corp DE now owns 332,099 shares of the biopharmaceutical company’s stock valued at $3,175,000 after purchasing an additional 14,054 shares during the period. Balyasny Asset Management L.P. bought a new position in Emergent Biosolutions in the 4th quarter valued at $127,000. Gotham Asset Management LLC bought a new position in Emergent Biosolutions in the 4th quarter valued at $200,000. Finally, Lazard Asset Management LLC grew its stake in Emergent Biosolutions by 541.0% in the 4th quarter. Lazard Asset Management LLC now owns 55,303 shares of the biopharmaceutical company’s stock valued at $528,000 after purchasing an additional 46,676 shares during the period. Institutional investors own 78.40% of the company’s stock.

Insider Buying and Selling at Emergent Biosolutions

In related news, Director Kathryn C. Zoon sold 7,086 shares of the business’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $8.87, for a total transaction of $62,852.82. Following the completion of the transaction, the director directly owned 71,799 shares in the company, valued at $636,857.13. The trade was a 8.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Donald W. Degolyer sold 7,844 shares of the business’s stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $8.65, for a total value of $67,850.60. Following the transaction, the director owned 137,659 shares of the company’s stock, valued at approximately $1,190,750.35. The trade was a 5.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by insiders.

Emergent Biosolutions Price Performance

Shares of NYSE EBS opened at $7.96 on Thursday. The stock has a market cap of $424.88 million, a PE ratio of 3.25 and a beta of 2.04. Emergent Biosolutions Inc. has a fifty-two week low of $4.02 and a fifty-two week high of $12.73. The company has a debt-to-equity ratio of 1.25, a quick ratio of 3.00 and a current ratio of 5.66. The stock has a fifty day moving average of $7.66 and a 200-day moving average of $6.43.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.16 earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.42. The company had revenue of $140.90 million during the quarter, compared to analysts’ expectations of $148.55 million. Emergent Biosolutions had a return on equity of 24.63% and a net margin of 16.38%. Equities research analysts anticipate that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Emergent Biosolutions in a research note on Wednesday, September 3rd. Wall Street Zen downgraded Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $14.33.

Emergent Biosolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.